Investment Thesis
Silexion is a pre-commercial stage biotech burning $10.8M annually with minimal revenue ($155K) and only 6-7 months of cash runway remaining. Extreme operating losses ($11.6M) relative to revenue, deteriorating net income trends, and absence of clear commercialization milestones indicate high failure risk without immediate capital infusion.
Strengths
- Zero long-term debt provides financial flexibility for future fundraising
- Current ratio of 2.41x ensures short-term operational stability
- Revenue growing 453.6% YoY indicates early market traction despite minimal absolute base
Risks
- Unsustainable cash burn of $10.8M annually against $6M cash balance = 6-7 month runway
- Operating losses of $11.6M exceed revenue by 75x, indicating pre-commercial or failed product stage
- Deteriorating profitability (net income down 200% YoY) with negative ROE (-457.6%) and ROA (-165.1%)
- Likely imminent dilutive equity raise required to prevent insolvency
- Minimal absolute revenue ($155K) suggests either early clinical trials or commercialization failure
Key Metrics to Watch
- Monthly cash burn rate and updated runway estimate
- Clinical trial progress or regulatory filing milestones
- Revenue trajectory acceleration post-453.6% YoY baseline
- Form 4 insider activity patterns (buying vs. selling)
- Capital raise announcements and dilution impact on equity
Financial Metrics
Revenue
155.0K
Net Income
-11.9M
EPS (Diluted)
$8.96
Free Cash Flow
-10.8M
Total Assets
7.2M
Cash
6.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-7,504.5%
Net Margin
-7,685.2%
ROE
-457.6%
ROA
-165.1%
FCF Margin
-6,985.8%
Balance Sheet & Liquidity
Current Ratio
2.41x
Quick Ratio
2.41x
Debt/Equity
0.00x
Debt/Assets
63.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T02:36:23.908722 |
Data as of: 2025-12-31 |
Powered by Claude AI